These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The discovery and development of zileuton: an orally active 5-lipoxygenase inhibitor. Bell RL; Young PR; Albert D; Lanni C; Summers JB; Brooks DW; Rubin P; Carter GW Int J Immunopharmacol; 1992 Apr; 14(3):505-10. PubMed ID: 1618602 [TBL] [Abstract][Full Text] [Related]
5. The properties of A-69412: a small hydrophilic 5-lipoxygenase inhibitor. Bell RL; Bouska J; Young PR; Lanni C; Machinist J; Malo PE; Summers JB; Brooks DW; Carter GW Agents Actions; 1993 Mar; 38(3-4):178-87. PubMed ID: 8213344 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, safety, and ability to diminish leukotriene synthesis by zileuton, an inhibitor of 5-lipoxygenase. Rubin P; Dubé L; Braeckman R; Swanson L; Hansen R; Albert D; Carter G Agents Actions Suppl; 1991; 35():103-16. PubMed ID: 1781415 [TBL] [Abstract][Full Text] [Related]
7. Inhibition by troglitazone of the antigen-induced production of leukotrienes in immunoglobulin E-sensitized RBL-2H3 cells. Yamashita M; Kushihara M; Hirasawa N; Takasaki W; Takahagi H; Takayanagi M; Ohuchi K Br J Pharmacol; 2000 Jan; 129(2):367-73. PubMed ID: 10694244 [TBL] [Abstract][Full Text] [Related]
9. Intrinsic 5-lipoxygenase activity is required for neutrophil responsivity. Guidot DM; Repine MJ; Westcott JY; Repine JE Proc Natl Acad Sci U S A; 1994 Aug; 91(17):8156-9. PubMed ID: 8058773 [TBL] [Abstract][Full Text] [Related]
10. Nasal secretion in ragweed-sensitized dogs: effect of leukotriene synthesis inhibition. Cardell LO; Agustí C; Nadel JA Acta Otolaryngol; 2000 Sep; 120(6):757-60. PubMed ID: 11099154 [TBL] [Abstract][Full Text] [Related]
11. Effects of the arachidonate 5-lipoxygenase synthesis inhibitor A-64077 in intestinal ischemia-reperfusion injury. Mangino MJ; Murphy MK; Anderson CB J Pharmacol Exp Ther; 1994 Apr; 269(1):75-81. PubMed ID: 8169854 [TBL] [Abstract][Full Text] [Related]
12. Anti-inflammatory activity of a potent, selective leukotriene A4 hydrolase inhibitor in comparison with the 5-lipoxygenase inhibitor zileuton. Rao NL; Dunford PJ; Xue X; Jiang X; Lundeen KA; Coles F; Riley JP; Williams KN; Grice CA; Edwards JP; Karlsson L; Fourie AM J Pharmacol Exp Ther; 2007 Jun; 321(3):1154-60. PubMed ID: 17371808 [TBL] [Abstract][Full Text] [Related]
13. Tenidap inhibits 5-lipoxygenase product formation in vitro, but this activity is not observed in three animal models. Carty TJ; Sweeney FJ; Griffiths RJ; Eskra JD; Ernest MJ; Pillar JS; Cheng JD; Loose LD; Joseph PA; Pazoles PP; Moore PF; Nagahisa A; Murase S; Kadin SB Inflamm Res; 1997 May; 46(5):168-79. PubMed ID: 9197987 [TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic and pharmacokinetic characterisation of RBx 7796: a novel 5-lipoxygenase inhibitor. Shirumalla RK; Sharma P; Dastidar SG; Paliwal JK; Kakar S; Varshney B; Singh Saini G; Sattigeri V; Salman M; Ray A Inflamm Res; 2008 Mar; 57(3):135-43. PubMed ID: 18369577 [TBL] [Abstract][Full Text] [Related]
15. The 5-lipoxygenase inhibitor zileuton blocks antigen-induced late airway responses, inflammation and airway hyperresponsiveness in allergic sheep. Abraham WM; Ahmed A; Cortes A; Sielczak MW; Hinz W; Bouska J; Lanni C; Bell RL Eur J Pharmacol; 1992 Jul; 217(2-3):119-26. PubMed ID: 1330588 [TBL] [Abstract][Full Text] [Related]
16. The effect of a selective 5-lipoxygenase inhibitor, zileuton, on tissue damage in acute colonic inflammation in rats. Zarif A; Eiznhamer D; Callaghan C; Doria MI; Broutman L; Keshavarzian A Inflammation; 1996 Jun; 20(3):217-27. PubMed ID: 8796377 [TBL] [Abstract][Full Text] [Related]
17. Optimization of the potency and duration of action of N-hydroxyurea 5-lipoxygenase inhibitors. Bell RL; Bouska JB; Malo PE; Lanni C; Harris RR; Otis ER; Stewart AO; Brooks DW; Carter GW J Pharmacol Exp Ther; 1995 Feb; 272(2):724-31. PubMed ID: 7853186 [TBL] [Abstract][Full Text] [Related]
18. A rat air pouch model for evaluating the efficacy and selectivity of 5-lipoxygenase inhibitors. Zweifel BS; Hardy MM; Anderson GD; Dufield DR; Pufahl RA; Masferrer JL Eur J Pharmacol; 2008 Apr; 584(1):166-74. PubMed ID: 18295198 [TBL] [Abstract][Full Text] [Related]
19. Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor. Knapp HR N Engl J Med; 1990 Dec; 323(25):1745-8. PubMed ID: 1701029 [TBL] [Abstract][Full Text] [Related]
20. Stereoselective metabolism of the 5-lipoxygenase inhibitor A-78773. Carter GW; Bell RL; Marsh K; Lanni C; Awni WM; Bouska J; Stewart AO; Hansen R; Dubé L; Brooks DW Ann N Y Acad Sci; 1994 Nov; 744():262-73. PubMed ID: 7825849 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]